Physician profile
Carlyn Newell
NPI 1649998139
$6,703.37
in general payments reported to CMS, 2019-2025
29 companies · $2,350 in 2025
The $2,350 reported for 2025 was more than what 96% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $1,013 · 2024: $3,211 · 2025: $2,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,823 · Travel and Lodging: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,822.78 |
| Travel and Lodging | $751.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,619.54 | 2023-2025 | Watchman Access System, Watchman Flx, Watchman |
| Actelion Pharmaceuticals US, INC. | $413.41 | 2023-2025 | Opsumit, Uptravi |
| Amgen INC. | $351.96 | 2023-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $347.05 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $337.70 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $314.49 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $272.64 | 2023-2025 | Verquvo, Capvaxive, Winrevair |
| Novartis Pharmaceuticals Corporation | $229.94 | 2023-2025 | |
| Novo Nordisk INC | $218.57 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $212.87 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $194.00 | 2023-2025 | Wainua, Brilinta, Farxiga |
| Pfizer INC. | $183.53 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $162.60 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.26 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $131.27 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $85.65 | 2023-2025 | Amvuttra, Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $70.90 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $55.54 | 2025 | Attruby |
| Shockwave Medical, INC | $53.32 | 2025 | |
| Abiomed | $48.52 | 2025 | |
| Cvrx, INC. | $44.56 | 2024 | Barostim Neo System |
| Heartflow, INC. | $43.17 | 2025 | |
| Lilly USA, LLC | $42.77 | 2025 | Zepbound, Mounjaro |
| Vital Connect, INC | $38.98 | 2025 | Vitalpatch Rtm |
| Lexicon Pharmaceuticals, INC. | $27.24 | 2023-2024 | Inpefa |
| Teleflex LLC | $22.95 | 2025 | Vascband |
| Tactile Systems Technology INC | $17.55 | 2024 | Flexitouch Plus, Entre Plus |
| Chiesi USA, INC. | $15.64 | 2024 | Kengreal, Cleviprex |
| Esperion Therapeutics, INC. | $13.75 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlyn Newell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.